nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—TEK—sarcoma	0.143	0.25	CbGaD
Regorafenib—FLT1—sarcoma	0.111	0.195	CbGaD
Regorafenib—PDGFRB—sarcoma	0.0922	0.161	CbGaD
Regorafenib—PDGFRA—sarcoma	0.0898	0.157	CbGaD
Regorafenib—KDR—sarcoma	0.0699	0.122	CbGaD
Regorafenib—KIT—sarcoma	0.0659	0.115	CbGaD
Regorafenib—CYP2B6—Thiotepa—sarcoma	0.032	0.167	CbGbCtD
Regorafenib—UGT1A1—Etoposide—sarcoma	0.0224	0.117	CbGbCtD
Regorafenib—ABCG2—Dactinomycin—sarcoma	0.0219	0.114	CbGbCtD
Regorafenib—ABCG2—Mitoxantrone—sarcoma	0.0196	0.102	CbGbCtD
Regorafenib—ABCG2—Vincristine—sarcoma	0.0135	0.0704	CbGbCtD
Regorafenib—ABCG2—Etoposide—sarcoma	0.0123	0.0645	CbGbCtD
Regorafenib—CYP3A4—Thiotepa—sarcoma	0.00983	0.0514	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—sarcoma	0.00841	0.044	CbGbCtD
Regorafenib—ABCB1—Dactinomycin—sarcoma	0.00788	0.0412	CbGbCtD
Regorafenib—ABCB1—Mitoxantrone—sarcoma	0.00705	0.0369	CbGbCtD
Regorafenib—CYP2C8—Etoposide—sarcoma	0.00657	0.0344	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—sarcoma	0.00592	0.0309	CbGbCtD
Regorafenib—ABCB1—Vincristine—sarcoma	0.00485	0.0254	CbGbCtD
Regorafenib—ABCB1—Etoposide—sarcoma	0.00445	0.0233	CbGbCtD
Regorafenib—CYP3A4—Mitoxantrone—sarcoma	0.00422	0.0221	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—sarcoma	0.00303	0.0159	CbGbCtD
Regorafenib—CYP3A4—Vincristine—sarcoma	0.00291	0.0152	CbGbCtD
Regorafenib—CYP3A4—Etoposide—sarcoma	0.00266	0.0139	CbGbCtD
Regorafenib—EPHA2—pulmonary artery—sarcoma	0.00198	0.0321	CbGeAlD
Regorafenib—CYP3A4—Doxorubicin—sarcoma	0.00182	0.0095	CbGbCtD
Regorafenib—FGFR2—skull—sarcoma	0.0014	0.0228	CbGeAlD
Regorafenib—FLT1—umbilical vein—sarcoma	0.00123	0.02	CbGeAlD
Regorafenib—Sorafenib—FLT1—sarcoma	0.00112	0.26	CrCbGaD
Regorafenib—KDR—umbilical vein—sarcoma	0.00104	0.0169	CbGeAlD
Regorafenib—DDR2—mammary gland—sarcoma	0.000994	0.0161	CbGeAlD
Regorafenib—KDR—hindlimb—sarcoma	0.000953	0.0155	CbGeAlD
Regorafenib—MAPK11—mammary gland—sarcoma	0.000942	0.0153	CbGeAlD
Regorafenib—Sorafenib—PDGFRB—sarcoma	0.000923	0.215	CrCbGaD
Regorafenib—Sorafenib—PDGFRA—sarcoma	0.0009	0.209	CrCbGaD
Regorafenib—KDR—appendage—sarcoma	0.000818	0.0133	CbGeAlD
Regorafenib—FLT4—endothelium—sarcoma	0.000751	0.0122	CbGeAlD
Regorafenib—DDR2—myometrium—sarcoma	0.000705	0.0114	CbGeAlD
Regorafenib—Sorafenib—KDR—sarcoma	0.0007	0.163	CrCbGaD
Regorafenib—FRK—hematopoietic system—sarcoma	0.000675	0.0109	CbGeAlD
Regorafenib—EPHX2—mammary gland—sarcoma	0.000671	0.0109	CbGeAlD
Regorafenib—Sorafenib—KIT—sarcoma	0.00066	0.154	CrCbGaD
Regorafenib—DDR2—hematopoietic system—sarcoma	0.000605	0.00982	CbGeAlD
Regorafenib—TEK—endothelium—sarcoma	0.000604	0.00979	CbGeAlD
Regorafenib—FLT1—endothelium—sarcoma	0.000584	0.00947	CbGeAlD
Regorafenib—DDR2—connective tissue—sarcoma	0.000583	0.00945	CbGeAlD
Regorafenib—RET—mammary gland—sarcoma	0.000534	0.00867	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—sarcoma	0.000533	0.00865	CbGeAlD
Regorafenib—DDR2—skin of body—sarcoma	0.000526	0.00854	CbGeAlD
Regorafenib—FGFR2—mammary gland—sarcoma	0.000508	0.00823	CbGeAlD
Regorafenib—EPHA2—mammary gland—sarcoma	0.000499	0.00809	CbGeAlD
Regorafenib—KDR—endothelium—sarcoma	0.000494	0.008	CbGeAlD
Regorafenib—TEK—mammary gland—sarcoma	0.000487	0.00789	CbGeAlD
Regorafenib—EPHX2—myometrium—sarcoma	0.000476	0.00772	CbGeAlD
Regorafenib—FRK—lymphoid tissue—sarcoma	0.000475	0.00771	CbGeAlD
Regorafenib—DDR2—uterus—sarcoma	0.000457	0.00742	CbGeAlD
Regorafenib—NTRK1—testis—sarcoma	0.000446	0.00724	CbGeAlD
Regorafenib—PDGFRA—mammary gland—sarcoma	0.000441	0.00715	CbGeAlD
Regorafenib—KIT—endothelium—sarcoma	0.000437	0.00709	CbGeAlD
Regorafenib—EPHX2—seminal vesicle—sarcoma	0.00043	0.00698	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—sarcoma	0.000426	0.00691	CbGeAlD
Regorafenib—FGFR1—myometrium—sarcoma	0.000424	0.00687	CbGeAlD
Regorafenib—FLT4—embryo—sarcoma	0.000413	0.0067	CbGeAlD
Regorafenib—DDR2—tendon—sarcoma	0.000401	0.0065	CbGeAlD
Regorafenib—KDR—mammary gland—sarcoma	0.000398	0.00645	CbGeAlD
Regorafenib—FRK—testis—sarcoma	0.00037	0.006	CbGeAlD
Regorafenib—FLT4—hematopoietic system—sarcoma	0.000369	0.00598	CbGeAlD
Regorafenib—RET—embryo—sarcoma	0.000365	0.00591	CbGeAlD
Regorafenib—EPHA2—myometrium—sarcoma	0.000354	0.00574	CbGeAlD
Regorafenib—KIT—mammary gland—sarcoma	0.000353	0.00572	CbGeAlD
Regorafenib—FRK—liver—sarcoma	0.00035	0.00567	CbGeAlD
Regorafenib—FGFR2—embryo—sarcoma	0.000347	0.00562	CbGeAlD
Regorafenib—PDGFRB—mammary gland—sarcoma	0.000344	0.00558	CbGeAlD
Regorafenib—FLT1—myometrium—sarcoma	0.000334	0.00542	CbGeAlD
Regorafenib—TEK—embryo—sarcoma	0.000332	0.00539	CbGeAlD
Regorafenib—RAF1—myometrium—sarcoma	0.000332	0.00538	CbGeAlD
Regorafenib—DDR2—testis—sarcoma	0.000332	0.00538	CbGeAlD
Regorafenib—RET—hematopoietic system—sarcoma	0.000326	0.00528	CbGeAlD
Regorafenib—BRAF—uterus—sarcoma	0.000323	0.00524	CbGeAlD
Regorafenib—FLT1—embryo—sarcoma	0.000321	0.00521	CbGeAlD
Regorafenib—EPHA2—seminal vesicle—sarcoma	0.00032	0.00519	CbGeAlD
Regorafenib—RAF1—embryo—sarcoma	0.000319	0.00518	CbGeAlD
Regorafenib—MAPK11—testis—sarcoma	0.000315	0.0051	CbGeAlD
Regorafenib—DDR2—liver—sarcoma	0.000314	0.00509	CbGeAlD
Regorafenib—RET—connective tissue—sarcoma	0.000313	0.00508	CbGeAlD
Regorafenib—FGFR2—hematopoietic system—sarcoma	0.000309	0.00502	CbGeAlD
Regorafenib—EPHX2—uterus—sarcoma	0.000309	0.00501	CbGeAlD
Regorafenib—ABL1—mammary gland—sarcoma	0.000307	0.00498	CbGeAlD
Regorafenib—EPHA2—hematopoietic system—sarcoma	0.000304	0.00493	CbGeAlD
Regorafenib—FLT1—seminal vesicle—sarcoma	0.000302	0.00489	CbGeAlD
Regorafenib—PDGFRA—embryo—sarcoma	0.000301	0.00488	CbGeAlD
Regorafenib—RAF1—seminal vesicle—sarcoma	0.0003	0.00486	CbGeAlD
Regorafenib—FGFR2—connective tissue—sarcoma	0.000298	0.00483	CbGeAlD
Regorafenib—TEK—hematopoietic system—sarcoma	0.000297	0.00481	CbGeAlD
Regorafenib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000289	0.173	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000289	0.173	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000289	0.173	CbGdCrCtD
Regorafenib—FLT1—hematopoietic system—sarcoma	0.000287	0.00465	CbGeAlD
Regorafenib—TEK—connective tissue—sarcoma	0.000286	0.00463	CbGeAlD
Regorafenib—RAF1—hematopoietic system—sarcoma	0.000285	0.00462	CbGeAlD
Regorafenib—BRAF—tendon—sarcoma	0.000283	0.00459	CbGeAlD
Regorafenib—KDR—myometrium—sarcoma	0.000282	0.00458	CbGeAlD
Regorafenib—FGFR1—cardiac atrium—sarcoma	0.000276	0.00448	CbGeAlD
Regorafenib—FLT1—connective tissue—sarcoma	0.000276	0.00448	CbGeAlD
Regorafenib—FGFR1—uterus—sarcoma	0.000275	0.00446	CbGeAlD
Regorafenib—RAF1—connective tissue—sarcoma	0.000274	0.00445	CbGeAlD
Regorafenib—BRAF—bone marrow—sarcoma	0.000274	0.00445	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—sarcoma	0.000272	0.00442	CbGeAlD
Regorafenib—KDR—embryo—sarcoma	0.000272	0.0044	CbGeAlD
Regorafenib—EPHX2—tendon—sarcoma	0.000271	0.00439	CbGeAlD
Regorafenib—FGFR2—skin of body—sarcoma	0.000269	0.00436	CbGeAlD
Regorafenib—PDGFRA—hematopoietic system—sarcoma	0.000269	0.00436	CbGeAlD
Regorafenib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000268	0.16	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000268	0.16	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000268	0.16	CbGdCrCtD
Regorafenib—TEK—smooth muscle tissue—sarcoma	0.000261	0.00424	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—sarcoma	0.00026	0.00421	CbGeAlD
Regorafenib—PDGFRA—connective tissue—sarcoma	0.000259	0.0042	CbGeAlD
Regorafenib—UGT1A1—hematopoietic system—sarcoma	0.000256	0.00416	CbGeAlD
Regorafenib—KDR—seminal vesicle—sarcoma	0.000255	0.00414	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—sarcoma	0.000253	0.0041	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—sarcoma	0.000251	0.00407	CbGeAlD
Regorafenib—KIT—myometrium—sarcoma	0.00025	0.00406	CbGeAlD
Regorafenib—RAF1—skin of body—sarcoma	0.000248	0.00402	CbGeAlD
Regorafenib—PDGFRB—myometrium—sarcoma	0.000244	0.00396	CbGeAlD
Regorafenib—KDR—hematopoietic system—sarcoma	0.000242	0.00393	CbGeAlD
Regorafenib—FGFR1—tendon—sarcoma	0.000241	0.0039	CbGeAlD
Regorafenib—KIT—embryo—sarcoma	0.000241	0.0039	CbGeAlD
Regorafenib—DDR2—lymph node—sarcoma	0.00024	0.0039	CbGeAlD
Regorafenib—PDGFRA—smooth muscle tissue—sarcoma	0.000237	0.00384	CbGeAlD
Regorafenib—FLT4—bone marrow—sarcoma	0.000236	0.00383	CbGeAlD
Regorafenib—PDGFRB—embryo—sarcoma	0.000235	0.00381	CbGeAlD
Regorafenib—BRAF—testis—sarcoma	0.000234	0.0038	CbGeAlD
Regorafenib—FGFR2—uterus—sarcoma	0.000234	0.00379	CbGeAlD
Regorafenib—KDR—connective tissue—sarcoma	0.000233	0.00378	CbGeAlD
Regorafenib—EPHA2—cardiac atrium—sarcoma	0.000231	0.00374	CbGeAlD
Regorafenib—RET—lymphoid tissue—sarcoma	0.000229	0.00372	CbGeAlD
Regorafenib—MAPK11—lymph node—sarcoma	0.000228	0.0037	CbGeAlD
Regorafenib—KIT—seminal vesicle—sarcoma	0.000226	0.00367	CbGeAlD
Regorafenib—TEK—cardiac atrium—sarcoma	0.000225	0.00365	CbGeAlD
Regorafenib—EPHX2—testis—sarcoma	0.000224	0.00363	CbGeAlD
Regorafenib—TEK—uterus—sarcoma	0.000224	0.00363	CbGeAlD
Regorafenib—BRAF—liver—sarcoma	0.000222	0.00359	CbGeAlD
Regorafenib—PDGFRB—seminal vesicle—sarcoma	0.000221	0.00358	CbGeAlD
Regorafenib—ABL1—myometrium—sarcoma	0.000218	0.00353	CbGeAlD
Regorafenib—FLT1—cardiac atrium—sarcoma	0.000218	0.00353	CbGeAlD
Regorafenib—FLT1—uterus—sarcoma	0.000217	0.00351	CbGeAlD
Regorafenib—RAF1—cardiac atrium—sarcoma	0.000216	0.00351	CbGeAlD
Regorafenib—Haemorrhage—Thiotepa—sarcoma	0.000216	0.00416	CcSEcCtD
Regorafenib—RET—tendon—sarcoma	0.000215	0.00349	CbGeAlD
Regorafenib—RAF1—uterus—sarcoma	0.000215	0.00349	CbGeAlD
Regorafenib—KIT—hematopoietic system—sarcoma	0.000215	0.00348	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—sarcoma	0.000214	0.00347	CbGeAlD
Regorafenib—Urinary tract disorder—Thiotepa—sarcoma	0.000214	0.00411	CcSEcCtD
Regorafenib—KDR—smooth muscle tissue—sarcoma	0.000214	0.00346	CbGeAlD
Regorafenib—Connective tissue disorder—Thiotepa—sarcoma	0.000213	0.00409	CcSEcCtD
Regorafenib—Urethral disorder—Thiotepa—sarcoma	0.000212	0.00408	CcSEcCtD
Regorafenib—EPHX2—liver—sarcoma	0.000212	0.00344	CbGeAlD
Regorafenib—Weight decreased—Mitoxantrone—sarcoma	0.000211	0.00406	CcSEcCtD
Regorafenib—Dysphonia—Epirubicin—sarcoma	0.000211	0.00405	CcSEcCtD
Regorafenib—Acute coronary syndrome—Vincristine—sarcoma	0.000211	0.00405	CcSEcCtD
Regorafenib—PDGFRB—hematopoietic system—sarcoma	0.00021	0.0034	CbGeAlD
Regorafenib—Myocardial infarction—Vincristine—sarcoma	0.000209	0.00403	CcSEcCtD
Regorafenib—ABL1—embryo—sarcoma	0.000209	0.0034	CbGeAlD
Regorafenib—TEK—lymphoid tissue—sarcoma	0.000209	0.00339	CbGeAlD
Regorafenib—Stomatitis—Vincristine—sarcoma	0.000208	0.00401	CcSEcCtD
Regorafenib—KIT—connective tissue—sarcoma	0.000207	0.00335	CbGeAlD
Regorafenib—Liver injury—Epirubicin—sarcoma	0.000206	0.00396	CcSEcCtD
Regorafenib—Acute coronary syndrome—Mitoxantrone—sarcoma	0.000205	0.00395	CcSEcCtD
Regorafenib—Myocardial infarction—Mitoxantrone—sarcoma	0.000204	0.00392	CcSEcCtD
Regorafenib—Erythema multiforme—Dactinomycin—sarcoma	0.000203	0.0039	CcSEcCtD
Regorafenib—PDGFRA—uterus—sarcoma	0.000203	0.00329	CbGeAlD
Regorafenib—Stomatitis—Mitoxantrone—sarcoma	0.000203	0.0039	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Etoposide—sarcoma	0.000202	0.00389	CcSEcCtD
Regorafenib—FLT4—testis—sarcoma	0.000202	0.00328	CbGeAlD
Regorafenib—PDGFRB—connective tissue—sarcoma	0.000202	0.00328	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—sarcoma	0.000202	0.00327	CbGeAlD
Regorafenib—EPHA2—tendon—sarcoma	0.000201	0.00326	CbGeAlD
Regorafenib—Cardiac disorder—Thiotepa—sarcoma	0.000201	0.00386	CcSEcCtD
Regorafenib—RAF1—lymphoid tissue—sarcoma	0.000201	0.00325	CbGeAlD
Regorafenib—FGFR1—testis—sarcoma	0.000199	0.00323	CbGeAlD
Regorafenib—CYP2C8—mammary gland—sarcoma	0.000199	0.00323	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Etoposide—sarcoma	0.000198	0.00381	CcSEcCtD
Regorafenib—ABL1—seminal vesicle—sarcoma	0.000197	0.00319	CbGeAlD
Regorafenib—TEK—tendon—sarcoma	0.000196	0.00318	CbGeAlD
Regorafenib—Angiopathy—Thiotepa—sarcoma	0.000196	0.00377	CcSEcCtD
Regorafenib—Dysphonia—Doxorubicin—sarcoma	0.000195	0.00375	CcSEcCtD
Regorafenib—Mediastinal disorder—Thiotepa—sarcoma	0.000195	0.00375	CcSEcCtD
Regorafenib—UGT1A9—liver—sarcoma	0.000194	0.00314	CbGeAlD
Regorafenib—Alopecia—Thiotepa—sarcoma	0.000191	0.00368	CcSEcCtD
Regorafenib—FLT4—liver—sarcoma	0.000191	0.0031	CbGeAlD
Regorafenib—Hyperbilirubinaemia—Epirubicin—sarcoma	0.000191	0.00367	CcSEcCtD
Regorafenib—Liver injury—Doxorubicin—sarcoma	0.000191	0.00367	CcSEcCtD
Regorafenib—FLT1—tendon—sarcoma	0.00019	0.00308	CbGeAlD
Regorafenib—Alopecia—Dactinomycin—sarcoma	0.00019	0.00365	CcSEcCtD
Regorafenib—Hypocalcaemia—Epirubicin—sarcoma	0.000189	0.00364	CcSEcCtD
Regorafenib—Urinary tract disorder—Vincristine—sarcoma	0.000189	0.00364	CcSEcCtD
Regorafenib—KIT—smooth muscle tissue—sarcoma	0.000189	0.00307	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—sarcoma	0.000189	0.00307	CbGeAlD
Regorafenib—RAF1—tendon—sarcoma	0.000189	0.00306	CbGeAlD
Regorafenib—Connective tissue disorder—Vincristine—sarcoma	0.000189	0.00363	CcSEcCtD
Regorafenib—FGFR1—liver—sarcoma	0.000189	0.00306	CbGeAlD
Regorafenib—Malnutrition—Thiotepa—sarcoma	0.000188	0.00362	CcSEcCtD
Regorafenib—Urethral disorder—Vincristine—sarcoma	0.000188	0.00362	CcSEcCtD
Regorafenib—Haemoglobin—Mitoxantrone—sarcoma	0.000188	0.00361	CcSEcCtD
Regorafenib—Hyperuricaemia—Epirubicin—sarcoma	0.000187	0.0036	CcSEcCtD
Regorafenib—ABL1—hematopoietic system—sarcoma	0.000187	0.00303	CbGeAlD
Regorafenib—Haemorrhage—Mitoxantrone—sarcoma	0.000187	0.00359	CcSEcCtD
Regorafenib—KIT—skin of body—sarcoma	0.000187	0.00303	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—sarcoma	0.000185	0.003	CbGeAlD
Regorafenib—KDR—cardiac atrium—sarcoma	0.000184	0.00298	CbGeAlD
Regorafenib—KDR—uterus—sarcoma	0.000183	0.00297	CbGeAlD
Regorafenib—RAF1—bone marrow—sarcoma	0.000183	0.00296	CbGeAlD
Regorafenib—PDGFRB—skin of body—sarcoma	0.000182	0.00296	CbGeAlD
Regorafenib—Neutropenia—Etoposide—sarcoma	0.000182	0.00349	CcSEcCtD
Regorafenib—ABL1—connective tissue—sarcoma	0.00018	0.00292	CbGeAlD
Regorafenib—RET—testis—sarcoma	0.000178	0.00289	CbGeAlD
Regorafenib—Cardiac disorder—Vincristine—sarcoma	0.000178	0.00342	CcSEcCtD
Regorafenib—PDGFRA—tendon—sarcoma	0.000178	0.00288	CbGeAlD
Regorafenib—CYP2C9—mammary gland—sarcoma	0.000177	0.00287	CbGeAlD
Regorafenib—Blood uric acid increased—Epirubicin—sarcoma	0.000177	0.0034	CcSEcCtD
Regorafenib—Hyperbilirubinaemia—Doxorubicin—sarcoma	0.000177	0.00339	CcSEcCtD
Regorafenib—Hypocalcaemia—Doxorubicin—sarcoma	0.000175	0.00337	CcSEcCtD
Regorafenib—Anaemia—Thiotepa—sarcoma	0.000174	0.00335	CcSEcCtD
Regorafenib—Angiopathy—Vincristine—sarcoma	0.000174	0.00335	CcSEcCtD
Regorafenib—Infestation NOS—Etoposide—sarcoma	0.000173	0.00333	CcSEcCtD
Regorafenib—Infestation—Etoposide—sarcoma	0.000173	0.00333	CcSEcCtD
Regorafenib—Hyperuricaemia—Doxorubicin—sarcoma	0.000173	0.00333	CcSEcCtD
Regorafenib—Mediastinal disorder—Vincristine—sarcoma	0.000173	0.00332	CcSEcCtD
Regorafenib—Anaemia—Dactinomycin—sarcoma	0.000173	0.00332	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Etoposide—sarcoma	0.000172	0.0033	CcSEcCtD
Regorafenib—KDR—lymphoid tissue—sarcoma	0.000171	0.00277	CbGeAlD
Regorafenib—Acute coronary syndrome—Etoposide—sarcoma	0.000171	0.00328	CcSEcCtD
Regorafenib—BRAF—lymph node—sarcoma	0.00017	0.00276	CbGeAlD
Regorafenib—Myocardial infarction—Etoposide—sarcoma	0.00017	0.00326	CcSEcCtD
Regorafenib—FGFR2—testis—sarcoma	0.00017	0.00275	CbGeAlD
Regorafenib—Alopecia—Vincristine—sarcoma	0.00017	0.00326	CcSEcCtD
Regorafenib—Stomatitis—Etoposide—sarcoma	0.000169	0.00325	CcSEcCtD
Regorafenib—Leukopenia—Thiotepa—sarcoma	0.000169	0.00324	CcSEcCtD
Regorafenib—Leukopenia—Dactinomycin—sarcoma	0.000167	0.00322	CcSEcCtD
Regorafenib—EPHA2—testis—sarcoma	0.000167	0.0027	CbGeAlD
Regorafenib—Alopecia—Mitoxantrone—sarcoma	0.000165	0.00317	CcSEcCtD
Regorafenib—ABL1—smooth muscle tissue—sarcoma	0.000165	0.00267	CbGeAlD
Regorafenib—Hepatobiliary disease—Etoposide—sarcoma	0.000164	0.00315	CcSEcCtD
Regorafenib—Blood uric acid increased—Doxorubicin—sarcoma	0.000163	0.00314	CcSEcCtD
Regorafenib—Hypertension—Thiotepa—sarcoma	0.000163	0.00313	CcSEcCtD
Regorafenib—ABL1—skin of body—sarcoma	0.000163	0.00264	CbGeAlD
Regorafenib—TEK—testis—sarcoma	0.000163	0.00264	CbGeAlD
Regorafenib—EPHX2—lymph node—sarcoma	0.000162	0.00263	CbGeAlD
Regorafenib—KIT—uterus—sarcoma	0.000162	0.00263	CbGeAlD
Regorafenib—KDR—tendon—sarcoma	0.00016	0.0026	CbGeAlD
Regorafenib—FGFR2—liver—sarcoma	0.00016	0.0026	CbGeAlD
Regorafenib—PDGFRB—cardiac atrium—sarcoma	0.000159	0.00258	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000159	0.00306	CcSEcCtD
Regorafenib—PDGFRB—uterus—sarcoma	0.000158	0.00257	CbGeAlD
Regorafenib—EPHA2—liver—sarcoma	0.000158	0.00255	CbGeAlD
Regorafenib—FLT1—testis—sarcoma	0.000157	0.00255	CbGeAlD
Regorafenib—Neoplasm—Epirubicin—sarcoma	0.000157	0.00302	CcSEcCtD
Regorafenib—RAF1—testis—sarcoma	0.000156	0.00253	CbGeAlD
Regorafenib—KDR—bone marrow—sarcoma	0.000155	0.00252	CbGeAlD
Regorafenib—Anaemia—Vincristine—sarcoma	0.000154	0.00297	CcSEcCtD
Regorafenib—TEK—liver—sarcoma	0.000154	0.00249	CbGeAlD
Regorafenib—Urinary tract disorder—Etoposide—sarcoma	0.000153	0.00295	CcSEcCtD
Regorafenib—Infection—Thiotepa—sarcoma	0.000153	0.00294	CcSEcCtD
Regorafenib—Urethral disorder—Etoposide—sarcoma	0.000152	0.00293	CcSEcCtD
Regorafenib—Infection—Dactinomycin—sarcoma	0.000152	0.00291	CcSEcCtD
Regorafenib—KIT—lymphoid tissue—sarcoma	0.000151	0.00245	CbGeAlD
Regorafenib—Nervous system disorder—Thiotepa—sarcoma	0.000151	0.0029	CcSEcCtD
Regorafenib—Thrombocytopenia—Thiotepa—sarcoma	0.00015	0.00289	CcSEcCtD
Regorafenib—Anaemia—Mitoxantrone—sarcoma	0.00015	0.00289	CcSEcCtD
Regorafenib—Leukopenia—Vincristine—sarcoma	0.000149	0.00287	CcSEcCtD
Regorafenib—Thrombocytopenia—Dactinomycin—sarcoma	0.000149	0.00287	CcSEcCtD
Regorafenib—Skin disorder—Thiotepa—sarcoma	0.000149	0.00287	CcSEcCtD
Regorafenib—FLT1—liver—sarcoma	0.000149	0.00241	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—sarcoma	0.000148	0.0024	CbGeAlD
Regorafenib—RAF1—liver—sarcoma	0.000148	0.0024	CbGeAlD
Regorafenib—PDGFRA—testis—sarcoma	0.000147	0.00239	CbGeAlD
Regorafenib—Erythema multiforme—Etoposide—sarcoma	0.000147	0.00283	CcSEcCtD
Regorafenib—FLT4—lymph node—sarcoma	0.000146	0.00238	CbGeAlD
Regorafenib—Leukopenia—Mitoxantrone—sarcoma	0.000146	0.0028	CcSEcCtD
Regorafenib—Neoplasm—Doxorubicin—sarcoma	0.000145	0.00279	CcSEcCtD
Regorafenib—FGFR1—lymph node—sarcoma	0.000145	0.00234	CbGeAlD
Regorafenib—Cardiac disorder—Etoposide—sarcoma	0.000144	0.00277	CcSEcCtD
Regorafenib—Hypertension—Vincristine—sarcoma	0.000144	0.00277	CcSEcCtD
Regorafenib—ABL1—cardiac atrium—sarcoma	0.000142	0.0023	CbGeAlD
Regorafenib—ABL1—uterus—sarcoma	0.000141	0.00229	CbGeAlD
Regorafenib—Angiopathy—Etoposide—sarcoma	0.000141	0.00271	CcSEcCtD
Regorafenib—Hypertension—Mitoxantrone—sarcoma	0.00014	0.0027	CcSEcCtD
Regorafenib—Mediastinal disorder—Etoposide—sarcoma	0.00014	0.00269	CcSEcCtD
Regorafenib—PDGFRA—liver—sarcoma	0.000139	0.00226	CbGeAlD
Regorafenib—CYP2C19—hematopoietic system—sarcoma	0.000139	0.00225	CbGeAlD
Regorafenib—PDGFRB—tendon—sarcoma	0.000139	0.00225	CbGeAlD
Regorafenib—KIT—bone marrow—sarcoma	0.000138	0.00223	CbGeAlD
Regorafenib—ABCG2—myometrium—sarcoma	0.000137	0.00223	CbGeAlD
Regorafenib—Alopecia—Etoposide—sarcoma	0.000137	0.00264	CcSEcCtD
Regorafenib—Infection—Vincristine—sarcoma	0.000135	0.0026	CcSEcCtD
Regorafenib—PDGFRB—bone marrow—sarcoma	0.000135	0.00218	CbGeAlD
Regorafenib—Nervous system disorder—Vincristine—sarcoma	0.000134	0.00257	CcSEcCtD
Regorafenib—Decreased appetite—Thiotepa—sarcoma	0.000134	0.00257	CcSEcCtD
Regorafenib—Thrombocytopenia—Vincristine—sarcoma	0.000133	0.00257	CcSEcCtD
Regorafenib—KDR—testis—sarcoma	0.000133	0.00215	CbGeAlD
Regorafenib—UGT1A1—liver—sarcoma	0.000133	0.00215	CbGeAlD
Regorafenib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000133	0.00255	CcSEcCtD
Regorafenib—Decreased appetite—Dactinomycin—sarcoma	0.000133	0.00255	CcSEcCtD
Regorafenib—Fatigue—Thiotepa—sarcoma	0.000133	0.00255	CcSEcCtD
Regorafenib—Infection—Mitoxantrone—sarcoma	0.000132	0.00254	CcSEcCtD
Regorafenib—ABL1—lymphoid tissue—sarcoma	0.000132	0.00213	CbGeAlD
Regorafenib—Fatigue—Dactinomycin—sarcoma	0.000132	0.00253	CcSEcCtD
Regorafenib—Pain—Thiotepa—sarcoma	0.000131	0.00253	CcSEcCtD
Regorafenib—Pain—Dactinomycin—sarcoma	0.00013	0.00251	CcSEcCtD
Regorafenib—Thrombocytopenia—Mitoxantrone—sarcoma	0.00013	0.0025	CcSEcCtD
Regorafenib—RET—lymph node—sarcoma	0.000129	0.0021	CbGeAlD
Regorafenib—Skin disorder—Mitoxantrone—sarcoma	0.000129	0.00248	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—sarcoma	0.000126	0.00243	CcSEcCtD
Regorafenib—Gastrointestinal pain—Thiotepa—sarcoma	0.000126	0.00242	CcSEcCtD
Regorafenib—KDR—liver—sarcoma	0.000126	0.00204	CbGeAlD
Regorafenib—Anaemia—Etoposide—sarcoma	0.000125	0.0024	CcSEcCtD
Regorafenib—Gastrointestinal pain—Dactinomycin—sarcoma	0.000125	0.0024	CcSEcCtD
Regorafenib—ABCG2—seminal vesicle—sarcoma	0.000124	0.00201	CbGeAlD
Regorafenib—ABL1—tendon—sarcoma	0.000124	0.00201	CbGeAlD
Regorafenib—Body temperature increased—Thiotepa—sarcoma	0.000122	0.00234	CcSEcCtD
Regorafenib—Abdominal pain—Thiotepa—sarcoma	0.000122	0.00234	CcSEcCtD
Regorafenib—CYP2C8—hematopoietic system—sarcoma	0.000121	0.00197	CbGeAlD
Regorafenib—Leukopenia—Etoposide—sarcoma	0.000121	0.00233	CcSEcCtD
Regorafenib—EPHA2—lymph node—sarcoma	0.000121	0.00196	CbGeAlD
Regorafenib—Body temperature increased—Dactinomycin—sarcoma	0.000121	0.00232	CcSEcCtD
Regorafenib—Abdominal pain—Dactinomycin—sarcoma	0.000121	0.00232	CcSEcCtD
Regorafenib—ABL1—bone marrow—sarcoma	0.00012	0.00194	CbGeAlD
Regorafenib—Decreased appetite—Vincristine—sarcoma	0.000118	0.00228	CcSEcCtD
Regorafenib—TEK—lymph node—sarcoma	0.000118	0.00191	CbGeAlD
Regorafenib—KIT—testis—sarcoma	0.000118	0.00191	CbGeAlD
Regorafenib—Gastrointestinal disorder—Vincristine—sarcoma	0.000118	0.00226	CcSEcCtD
Regorafenib—Fatigue—Vincristine—sarcoma	0.000118	0.00226	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—sarcoma	0.000117	0.00225	CcSEcCtD
Regorafenib—Hypertension—Etoposide—sarcoma	0.000117	0.00225	CcSEcCtD
Regorafenib—Pain—Vincristine—sarcoma	0.000117	0.00224	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—sarcoma	0.000115	0.00222	CcSEcCtD
Regorafenib—Decreased appetite—Mitoxantrone—sarcoma	0.000115	0.00222	CcSEcCtD
Regorafenib—PDGFRB—testis—sarcoma	0.000115	0.00186	CbGeAlD
Regorafenib—Hypokalaemia—Epirubicin—sarcoma	0.000115	0.0022	CcSEcCtD
Regorafenib—Fatigue—Mitoxantrone—sarcoma	0.000114	0.0022	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000114	0.0022	CcSEcCtD
Regorafenib—FLT1—lymph node—sarcoma	0.000114	0.00185	CbGeAlD
Regorafenib—Pain—Mitoxantrone—sarcoma	0.000114	0.00218	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000113	0.00218	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000113	0.00218	CcSEcCtD
Regorafenib—RAF1—lymph node—sarcoma	0.000113	0.00184	CbGeAlD
Regorafenib—Gastrointestinal pain—Vincristine—sarcoma	0.000111	0.00214	CcSEcCtD
Regorafenib—KIT—liver—sarcoma	0.000111	0.0018	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000111	0.00214	CcSEcCtD
Regorafenib—Asthenia—Thiotepa—sarcoma	0.00011	0.00212	CcSEcCtD
Regorafenib—Infection—Etoposide—sarcoma	0.00011	0.00211	CcSEcCtD
Regorafenib—Asthenia—Dactinomycin—sarcoma	0.000109	0.0021	CcSEcCtD
Regorafenib—CYP2B6—hematopoietic system—sarcoma	0.000109	0.00176	CbGeAlD
Regorafenib—PDGFRB—liver—sarcoma	0.000109	0.00176	CbGeAlD
Regorafenib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000109	0.00209	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—sarcoma	0.000108	0.00208	CcSEcCtD
Regorafenib—Body temperature increased—Vincristine—sarcoma	0.000108	0.00207	CcSEcCtD
Regorafenib—Abdominal pain—Vincristine—sarcoma	0.000108	0.00207	CcSEcCtD
Regorafenib—CYP2C9—hematopoietic system—sarcoma	0.000108	0.00175	CbGeAlD
Regorafenib—Skin disorder—Etoposide—sarcoma	0.000107	0.00206	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—sarcoma	0.000107	0.00205	CcSEcCtD
Regorafenib—PDGFRA—lymph node—sarcoma	0.000107	0.00173	CbGeAlD
Regorafenib—Hypokalaemia—Doxorubicin—sarcoma	0.000106	0.00204	CcSEcCtD
Regorafenib—Diarrhoea—Thiotepa—sarcoma	0.000105	0.00202	CcSEcCtD
Regorafenib—Abdominal pain—Mitoxantrone—sarcoma	0.000105	0.00202	CcSEcCtD
Regorafenib—Body temperature increased—Mitoxantrone—sarcoma	0.000105	0.00202	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000105	0.00202	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000105	0.00202	CcSEcCtD
Regorafenib—Diarrhoea—Dactinomycin—sarcoma	0.000104	0.00201	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000103	0.00198	CcSEcCtD
Regorafenib—ABL1—testis—sarcoma	0.000102	0.00166	CbGeAlD
Regorafenib—Neutropenia—Epirubicin—sarcoma	0.000102	0.00196	CcSEcCtD
Regorafenib—Weight decreased—Epirubicin—sarcoma	9.85e-05	0.00189	CcSEcCtD
Regorafenib—Asthenia—Vincristine—sarcoma	9.78e-05	0.00188	CcSEcCtD
Regorafenib—Vomiting—Thiotepa—sarcoma	9.77e-05	0.00188	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—sarcoma	9.7e-05	0.00187	CcSEcCtD
Regorafenib—Infestation—Epirubicin—sarcoma	9.7e-05	0.00187	CcSEcCtD
Regorafenib—Vomiting—Dactinomycin—sarcoma	9.7e-05	0.00187	CcSEcCtD
Regorafenib—Rash—Thiotepa—sarcoma	9.69e-05	0.00186	CcSEcCtD
Regorafenib—ABL1—liver—sarcoma	9.69e-05	0.00157	CbGeAlD
Regorafenib—Dermatitis—Thiotepa—sarcoma	9.68e-05	0.00186	CcSEcCtD
Regorafenib—Headache—Thiotepa—sarcoma	9.63e-05	0.00185	CcSEcCtD
Regorafenib—KDR—lymph node—sarcoma	9.63e-05	0.00156	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—sarcoma	9.62e-05	0.00185	CcSEcCtD
Regorafenib—Rash—Dactinomycin—sarcoma	9.62e-05	0.00185	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—sarcoma	9.6e-05	0.00185	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—sarcoma	9.53e-05	0.00183	CcSEcCtD
Regorafenib—Asthenia—Mitoxantrone—sarcoma	9.52e-05	0.00183	CcSEcCtD
Regorafenib—Fatigue—Etoposide—sarcoma	9.52e-05	0.00183	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—sarcoma	9.46e-05	0.00182	CcSEcCtD
Regorafenib—CYP2B6—skin of body—sarcoma	9.46e-05	0.00153	CbGeAlD
Regorafenib—Pain—Etoposide—sarcoma	9.44e-05	0.00182	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—sarcoma	9.42e-05	0.00181	CcSEcCtD
Regorafenib—Diarrhoea—Vincristine—sarcoma	9.33e-05	0.00179	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—sarcoma	9.18e-05	0.00176	CcSEcCtD
Regorafenib—Nausea—Thiotepa—sarcoma	9.13e-05	0.00176	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—sarcoma	9.11e-05	0.00175	CcSEcCtD
Regorafenib—Diarrhoea—Mitoxantrone—sarcoma	9.08e-05	0.00175	CcSEcCtD
Regorafenib—Nausea—Dactinomycin—sarcoma	9.06e-05	0.00174	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—sarcoma	9.03e-05	0.00174	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—sarcoma	8.98e-05	0.00173	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—sarcoma	8.98e-05	0.00173	CcSEcCtD
Regorafenib—ABCG2—uterus—sarcoma	8.91e-05	0.00144	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	8.9e-05	0.00171	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—sarcoma	8.76e-05	0.00168	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—sarcoma	8.75e-05	0.00168	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—sarcoma	8.73e-05	0.00168	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—sarcoma	8.73e-05	0.00168	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—sarcoma	8.71e-05	0.00168	CcSEcCtD
Regorafenib—Vomiting—Vincristine—sarcoma	8.67e-05	0.00167	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—sarcoma	8.6e-05	0.00165	CcSEcCtD
Regorafenib—Rash—Vincristine—sarcoma	8.59e-05	0.00165	CcSEcCtD
Regorafenib—Dermatitis—Vincristine—sarcoma	8.59e-05	0.00165	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—sarcoma	8.56e-05	0.00165	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—sarcoma	8.54e-05	0.00164	CcSEcCtD
Regorafenib—Headache—Vincristine—sarcoma	8.54e-05	0.00164	CcSEcCtD
Regorafenib—KIT—lymph node—sarcoma	8.53e-05	0.00138	CbGeAlD
Regorafenib—Hepatobiliary disease—Doxorubicin—sarcoma	8.49e-05	0.00163	CcSEcCtD
Regorafenib—Vomiting—Mitoxantrone—sarcoma	8.44e-05	0.00162	CcSEcCtD
Regorafenib—Rash—Mitoxantrone—sarcoma	8.37e-05	0.00161	CcSEcCtD
Regorafenib—Dermatitis—Mitoxantrone—sarcoma	8.36e-05	0.00161	CcSEcCtD
Regorafenib—PDGFRB—lymph node—sarcoma	8.33e-05	0.00135	CbGeAlD
Regorafenib—Headache—Mitoxantrone—sarcoma	8.32e-05	0.0016	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—sarcoma	8.24e-05	0.00158	CcSEcCtD
Regorafenib—CYP3A4—hematopoietic system—sarcoma	8.22e-05	0.00133	CbGeAlD
Regorafenib—Haemoglobin—Doxorubicin—sarcoma	8.1e-05	0.00156	CcSEcCtD
Regorafenib—Nausea—Vincristine—sarcoma	8.1e-05	0.00156	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—sarcoma	8.08e-05	0.00155	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—sarcoma	8.06e-05	0.00155	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—sarcoma	7.96e-05	0.00153	CcSEcCtD
Regorafenib—Asthenia—Etoposide—sarcoma	7.92e-05	0.00152	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—sarcoma	7.92e-05	0.00152	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—sarcoma	7.9e-05	0.00152	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—sarcoma	7.9e-05	0.00152	CcSEcCtD
Regorafenib—Nausea—Mitoxantrone—sarcoma	7.88e-05	0.00152	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—sarcoma	7.85e-05	0.00151	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—sarcoma	7.7e-05	0.00148	CcSEcCtD
Regorafenib—CYP2B6—lymphoid tissue—sarcoma	7.66e-05	0.00124	CbGeAlD
Regorafenib—Erythema multiforme—Doxorubicin—sarcoma	7.62e-05	0.00147	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—sarcoma	7.58e-05	0.00146	CcSEcCtD
Regorafenib—ABCG2—bone marrow—sarcoma	7.56e-05	0.00123	CbGeAlD
Regorafenib—Diarrhoea—Etoposide—sarcoma	7.55e-05	0.00145	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—sarcoma	7.48e-05	0.00144	CcSEcCtD
Regorafenib—ABL1—lymph node—sarcoma	7.43e-05	0.0012	CbGeAlD
Regorafenib—Angiopathy—Doxorubicin—sarcoma	7.31e-05	0.00141	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—sarcoma	7.26e-05	0.0014	CcSEcCtD
Regorafenib—CYP2C19—liver—sarcoma	7.2e-05	0.00117	CbGeAlD
Regorafenib—Alopecia—Doxorubicin—sarcoma	7.12e-05	0.00137	CcSEcCtD
Regorafenib—Vomiting—Etoposide—sarcoma	7.02e-05	0.00135	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—sarcoma	7.02e-05	0.00135	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—sarcoma	7.01e-05	0.00135	CcSEcCtD
Regorafenib—Rash—Etoposide—sarcoma	6.96e-05	0.00134	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—sarcoma	6.96e-05	0.00134	CcSEcCtD
Regorafenib—Headache—Etoposide—sarcoma	6.92e-05	0.00133	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—sarcoma	6.79e-05	0.00131	CcSEcCtD
Regorafenib—ABCB1—myometrium—sarcoma	6.77e-05	0.0011	CbGeAlD
Regorafenib—CYP2C8—testis—sarcoma	6.65e-05	0.00108	CbGeAlD
Regorafenib—Nausea—Etoposide—sarcoma	6.56e-05	0.00126	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—sarcoma	6.55e-05	0.00126	CcSEcCtD
Regorafenib—ABCB1—embryo—sarcoma	6.51e-05	0.00106	CbGeAlD
Regorafenib—Anaemia—Doxorubicin—sarcoma	6.49e-05	0.00125	CcSEcCtD
Regorafenib—ABCG2—testis—sarcoma	6.46e-05	0.00105	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.41e-05	0.00123	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—sarcoma	6.31e-05	0.00121	CcSEcCtD
Regorafenib—CYP2C8—liver—sarcoma	6.28e-05	0.00102	CbGeAlD
Regorafenib—Leukopenia—Doxorubicin—sarcoma	6.28e-05	0.00121	CcSEcCtD
Regorafenib—Infection—Epirubicin—sarcoma	6.15e-05	0.00118	CcSEcCtD
Regorafenib—ABCB1—seminal vesicle—sarcoma	6.12e-05	0.000992	CbGeAlD
Regorafenib—ABCG2—liver—sarcoma	6.11e-05	0.000991	CbGeAlD
Regorafenib—Nervous system disorder—Epirubicin—sarcoma	6.07e-05	0.00117	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—sarcoma	6.06e-05	0.00117	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—sarcoma	6.06e-05	0.00116	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—sarcoma	6.01e-05	0.00116	CcSEcCtD
Regorafenib—CYP2B6—testis—sarcoma	5.96e-05	0.000967	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	5.93e-05	0.00114	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—sarcoma	5.84e-05	0.00112	CcSEcCtD
Regorafenib—ABCB1—hematopoietic system—sarcoma	5.82e-05	0.000943	CbGeAlD
Regorafenib—Infection—Doxorubicin—sarcoma	5.69e-05	0.00109	CcSEcCtD
Regorafenib—CYP2B6—liver—sarcoma	5.64e-05	0.000914	CbGeAlD
Regorafenib—Nervous system disorder—Doxorubicin—sarcoma	5.62e-05	0.00108	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—sarcoma	5.61e-05	0.00108	CcSEcCtD
Regorafenib—CYP2C9—liver—sarcoma	5.58e-05	0.000905	CbGeAlD
Regorafenib—Skin disorder—Doxorubicin—sarcoma	5.56e-05	0.00107	CcSEcCtD
Regorafenib—Decreased appetite—Epirubicin—sarcoma	5.38e-05	0.00103	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—sarcoma	5.34e-05	0.00103	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—sarcoma	5.34e-05	0.00103	CcSEcCtD
Regorafenib—Pain—Epirubicin—sarcoma	5.29e-05	0.00102	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—sarcoma	5.06e-05	0.000973	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—sarcoma	4.98e-05	0.000957	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—sarcoma	4.94e-05	0.000951	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—sarcoma	4.94e-05	0.000949	CcSEcCtD
Regorafenib—Pain—Doxorubicin—sarcoma	4.9e-05	0.000942	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—sarcoma	4.89e-05	0.000941	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—sarcoma	4.89e-05	0.000941	CcSEcCtD
Regorafenib—ABCG2—lymph node—sarcoma	4.68e-05	0.00076	CbGeAlD
Regorafenib—Gastrointestinal pain—Doxorubicin—sarcoma	4.68e-05	0.000901	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—sarcoma	4.53e-05	0.000871	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—sarcoma	4.53e-05	0.000871	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—sarcoma	4.44e-05	0.000854	CcSEcCtD
Regorafenib—ABCB1—uterus—sarcoma	4.39e-05	0.000712	CbGeAlD
Regorafenib—CYP3A4—liver—sarcoma	4.26e-05	0.00069	CbGeAlD
Regorafenib—Diarrhoea—Epirubicin—sarcoma	4.23e-05	0.000814	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—sarcoma	4.11e-05	0.00079	CcSEcCtD
Regorafenib—ABCB1—lymphoid tissue—sarcoma	4.09e-05	0.000664	CbGeAlD
Regorafenib—Vomiting—Epirubicin—sarcoma	3.94e-05	0.000757	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—sarcoma	3.92e-05	0.000753	CcSEcCtD
Regorafenib—Rash—Epirubicin—sarcoma	3.9e-05	0.00075	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—sarcoma	3.9e-05	0.00075	CcSEcCtD
Regorafenib—Headache—Epirubicin—sarcoma	3.88e-05	0.000746	CcSEcCtD
Regorafenib—ABCB1—bone marrow—sarcoma	3.73e-05	0.000604	CbGeAlD
Regorafenib—Nausea—Epirubicin—sarcoma	3.68e-05	0.000707	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—sarcoma	3.64e-05	0.0007	CcSEcCtD
Regorafenib—Rash—Doxorubicin—sarcoma	3.61e-05	0.000694	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—sarcoma	3.61e-05	0.000694	CcSEcCtD
Regorafenib—Headache—Doxorubicin—sarcoma	3.59e-05	0.00069	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—sarcoma	3.4e-05	0.000654	CcSEcCtD
Regorafenib—ABCB1—testis—sarcoma	3.19e-05	0.000517	CbGeAlD
Regorafenib—ABCB1—liver—sarcoma	3.01e-05	0.000489	CbGeAlD
Regorafenib—ABCB1—lymph node—sarcoma	2.31e-05	0.000375	CbGeAlD
Regorafenib—PDGFRA—Signaling Pathways—KIT—sarcoma	2.53e-06	2.16e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HRAS—sarcoma	2.51e-06	2.15e-05	CbGpPWpGaD
Regorafenib—MAPK11—Gene Expression—MYC—sarcoma	2.51e-06	2.15e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCND1—sarcoma	2.5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ENO2—sarcoma	2.5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—JUN—sarcoma	2.5e-06	2.14e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—NRAS—sarcoma	2.49e-06	2.13e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HBA1—sarcoma	2.48e-06	2.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL2—sarcoma	2.48e-06	2.12e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CTNNB1—sarcoma	2.48e-06	2.12e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—NRAS—sarcoma	2.48e-06	2.12e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MDM2—sarcoma	2.47e-06	2.12e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KDR—sarcoma	2.47e-06	2.12e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EGFR—sarcoma	2.47e-06	2.11e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—CTNNB1—sarcoma	2.46e-06	2.11e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—CTNNB1—sarcoma	2.45e-06	2.1e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—NRAS—sarcoma	2.44e-06	2.09e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PLCG1—sarcoma	2.43e-06	2.08e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL2—sarcoma	2.43e-06	2.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL2—sarcoma	2.42e-06	2.07e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL2—sarcoma	2.42e-06	2.07e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CREB1—sarcoma	2.41e-06	2.07e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—JUN—sarcoma	2.41e-06	2.06e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—SRC—sarcoma	2.41e-06	2.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CREB1—sarcoma	2.41e-06	2.06e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—SRC—sarcoma	2.4e-06	2.06e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—CTNNB1—sarcoma	2.39e-06	2.05e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—SRC—sarcoma	2.39e-06	2.04e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCND1—sarcoma	2.36e-06	2.02e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—JUN—sarcoma	2.36e-06	2.02e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—JUN—sarcoma	2.35e-06	2.01e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—SRC—sarcoma	2.34e-06	2.01e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CTNNB1—sarcoma	2.34e-06	2e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—sarcoma	2.34e-06	2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MDM2—sarcoma	2.33e-06	2e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CTNNB1—sarcoma	2.33e-06	2e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ENO2—sarcoma	2.33e-06	2e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HRAS—sarcoma	2.33e-06	1.99e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—KRAS—sarcoma	2.33e-06	1.99e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HBA1—sarcoma	2.32e-06	1.98e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—NRAS—sarcoma	2.32e-06	1.98e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MDM2—sarcoma	2.31e-06	1.98e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—NRAS—sarcoma	2.31e-06	1.98e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—MYC—sarcoma	2.31e-06	1.97e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—NRAS—sarcoma	2.3e-06	1.96e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MDM2—sarcoma	2.28e-06	1.96e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KIT—sarcoma	2.28e-06	1.95e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EGFR—sarcoma	2.27e-06	1.94e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EGFR—sarcoma	2.26e-06	1.93e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—NRAS—sarcoma	2.25e-06	1.93e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—SRC—sarcoma	2.24e-06	1.92e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HRAS—sarcoma	2.24e-06	1.92e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HRAS—sarcoma	2.24e-06	1.92e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EGFR—sarcoma	2.22e-06	1.9e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—SRC—sarcoma	2.22e-06	1.9e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—SRC—sarcoma	2.22e-06	1.9e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL2—sarcoma	2.21e-06	1.89e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CTNNB1—sarcoma	2.21e-06	1.89e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KDR—sarcoma	2.21e-06	1.89e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—VEGFA—sarcoma	2.18e-06	1.87e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PLCG1—sarcoma	2.17e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CREB1—sarcoma	2.17e-06	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—SRC—sarcoma	2.16e-06	1.85e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—NRAS—sarcoma	2.15e-06	1.84e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—JUN—sarcoma	2.15e-06	1.84e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MDM2—sarcoma	2.14e-06	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—KRAS—sarcoma	2.14e-06	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—NRAS—sarcoma	2.14e-06	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—MYC—sarcoma	2.14e-06	1.83e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CTNNB1—sarcoma	2.13e-06	1.83e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—NRAS—sarcoma	2.13e-06	1.83e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—KRAS—sarcoma	2.13e-06	1.82e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PLCG1—sarcoma	2.12e-06	1.81e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—SRC—sarcoma	2.12e-06	1.81e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EGFR—sarcoma	2.11e-06	1.81e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—SRC—sarcoma	2.11e-06	1.81e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EGFR—sarcoma	2.11e-06	1.8e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MDM2—sarcoma	2.1e-06	1.8e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—KRAS—sarcoma	2.1e-06	1.8e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—MYC—sarcoma	2.1e-06	1.8e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EGFR—sarcoma	2.09e-06	1.79e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL2—sarcoma	2.09e-06	1.78e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—NRAS—sarcoma	2.08e-06	1.78e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL2—sarcoma	2.07e-06	1.77e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—VEGFA—sarcoma	2.06e-06	1.76e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EGFR—sarcoma	2.05e-06	1.76e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—NRAS—sarcoma	2.04e-06	1.74e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCND1—sarcoma	2.03e-06	1.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KIT—sarcoma	2.03e-06	1.74e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—NRAS—sarcoma	2.03e-06	1.74e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—NRAS—sarcoma	2.03e-06	1.74e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—JUN—sarcoma	2.03e-06	1.74e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCND1—sarcoma	2.01e-06	1.72e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CTNNB1—sarcoma	2.01e-06	1.72e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—JUN—sarcoma	2.01e-06	1.72e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—MYC—sarcoma	2.01e-06	1.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—SRC—sarcoma	2e-06	1.71e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MDM2—sarcoma	2e-06	1.71e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CTNNB1—sarcoma	1.99e-06	1.71e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—KRAS—sarcoma	1.99e-06	1.71e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—MYC—sarcoma	1.99e-06	1.71e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MDM2—sarcoma	1.99e-06	1.7e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—KRAS—sarcoma	1.99e-06	1.7e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—MYC—sarcoma	1.99e-06	1.7e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—sarcoma	1.98e-06	1.7e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PLCG1—sarcoma	1.98e-06	1.69e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—KRAS—sarcoma	1.98e-06	1.69e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CTNNB1—sarcoma	1.97e-06	1.69e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EGFR—sarcoma	1.96e-06	1.68e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EGFR—sarcoma	1.95e-06	1.67e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EGFR—sarcoma	1.94e-06	1.66e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—KRAS—sarcoma	1.94e-06	1.66e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CREB1—sarcoma	1.93e-06	1.65e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—SRC—sarcoma	1.93e-06	1.65e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—NRAS—sarcoma	1.92e-06	1.65e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL2—sarcoma	1.91e-06	1.64e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EGFR—sarcoma	1.9e-06	1.62e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—MYC—sarcoma	1.9e-06	1.62e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL2—sarcoma	1.88e-06	1.61e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCND1—sarcoma	1.87e-06	1.6e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—JUN—sarcoma	1.86e-06	1.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—NRAS—sarcoma	1.86e-06	1.59e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EGFR—sarcoma	1.85e-06	1.59e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—KRAS—sarcoma	1.85e-06	1.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—EGFR—sarcoma	1.85e-06	1.58e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EGFR—sarcoma	1.85e-06	1.58e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CTNNB1—sarcoma	1.85e-06	1.58e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—KRAS—sarcoma	1.84e-06	1.58e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—KRAS—sarcoma	1.84e-06	1.57e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCND1—sarcoma	1.83e-06	1.57e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—JUN—sarcoma	1.83e-06	1.57e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—SRC—sarcoma	1.82e-06	1.56e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—sarcoma	1.82e-06	1.56e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CTNNB1—sarcoma	1.82e-06	1.55e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—sarcoma	1.81e-06	1.55e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—SRC—sarcoma	1.8e-06	1.54e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.79e-06	1.54e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—KRAS—sarcoma	1.79e-06	1.53e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—MYC—sarcoma	1.79e-06	1.53e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—sarcoma	1.79e-06	1.53e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL2—sarcoma	1.78e-06	1.53e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—SRC—sarcoma	1.78e-06	1.52e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL2—sarcoma	1.78e-06	1.52e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—VEGFA—sarcoma	1.77e-06	1.52e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—VEGFA—sarcoma	1.76e-06	1.5e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—KRAS—sarcoma	1.75e-06	1.5e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EGFR—sarcoma	1.75e-06	1.5e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NRAS—sarcoma	1.75e-06	1.5e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—KRAS—sarcoma	1.75e-06	1.5e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—KRAS—sarcoma	1.75e-06	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCND1—sarcoma	1.74e-06	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—sarcoma	1.74e-06	1.49e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCND1—sarcoma	1.74e-06	1.49e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NRAS—sarcoma	1.73e-06	1.48e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—sarcoma	1.73e-06	1.48e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CTNNB1—sarcoma	1.72e-06	1.47e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CTNNB1—sarcoma	1.72e-06	1.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NRAS—sarcoma	1.71e-06	1.47e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—sarcoma	1.7e-06	1.45e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—sarcoma	1.69e-06	1.45e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—sarcoma	1.69e-06	1.45e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—sarcoma	1.68e-06	1.44e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—SRC—sarcoma	1.67e-06	1.43e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—sarcoma	1.65e-06	1.42e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—sarcoma	1.65e-06	1.41e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—sarcoma	1.65e-06	1.41e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—SRC—sarcoma	1.64e-06	1.4e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—sarcoma	1.63e-06	1.4e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—sarcoma	1.63e-06	1.39e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—sarcoma	1.62e-06	1.38e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NRAS—sarcoma	1.61e-06	1.38e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL2—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MDM2—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—sarcoma	1.6e-06	1.37e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—sarcoma	1.58e-06	1.35e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NRAS—sarcoma	1.58e-06	1.35e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—sarcoma	1.58e-06	1.35e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—sarcoma	1.57e-06	1.34e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—sarcoma	1.56e-06	1.34e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—sarcoma	1.56e-06	1.34e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—sarcoma	1.56e-06	1.34e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—sarcoma	1.56e-06	1.34e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—sarcoma	1.56e-06	1.33e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—sarcoma	1.56e-06	1.33e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—sarcoma	1.55e-06	1.33e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	1.55e-06	1.32e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—sarcoma	1.54e-06	1.32e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HBA1—sarcoma	1.53e-06	1.31e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—sarcoma	1.52e-06	1.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—sarcoma	1.52e-06	1.3e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—sarcoma	1.51e-06	1.29e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—sarcoma	1.51e-06	1.29e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—sarcoma	1.5e-06	1.28e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—sarcoma	1.5e-06	1.28e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—sarcoma	1.49e-06	1.28e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—sarcoma	1.49e-06	1.28e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—sarcoma	1.49e-06	1.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—sarcoma	1.49e-06	1.27e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—sarcoma	1.48e-06	1.27e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—sarcoma	1.47e-06	1.26e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—sarcoma	1.47e-06	1.26e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—sarcoma	1.46e-06	1.25e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—sarcoma	1.44e-06	1.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—sarcoma	1.43e-06	1.22e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—sarcoma	1.41e-06	1.2e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—sarcoma	1.4e-06	1.2e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—sarcoma	1.4e-06	1.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—sarcoma	1.39e-06	1.19e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—sarcoma	1.39e-06	1.19e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—sarcoma	1.39e-06	1.19e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—sarcoma	1.38e-06	1.18e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CTNNB1—sarcoma	1.38e-06	1.18e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—sarcoma	1.37e-06	1.17e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	1.36e-06	1.17e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—sarcoma	1.36e-06	1.17e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—sarcoma	1.36e-06	1.16e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—sarcoma	1.36e-06	1.16e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—sarcoma	1.35e-06	1.15e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—sarcoma	1.34e-06	1.15e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—sarcoma	1.33e-06	1.14e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PLCG1—sarcoma	1.31e-06	1.12e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—sarcoma	1.29e-06	1.1e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—sarcoma	1.29e-06	1.1e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—sarcoma	1.28e-06	1.1e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—sarcoma	1.27e-06	1.09e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—sarcoma	1.25e-06	1.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—sarcoma	1.25e-06	1.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—sarcoma	1.25e-06	1.07e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—sarcoma	1.23e-06	1.05e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—sarcoma	1.23e-06	1.05e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—sarcoma	1.21e-06	1.04e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—sarcoma	1.21e-06	1.03e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—sarcoma	1.2e-06	1.03e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—sarcoma	1.18e-06	1.01e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—sarcoma	1.16e-06	9.92e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—sarcoma	1.15e-06	9.88e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—sarcoma	1.15e-06	9.81e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—sarcoma	1.14e-06	9.78e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—sarcoma	1.12e-06	9.57e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—sarcoma	1.1e-06	9.38e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—sarcoma	1.09e-06	9.36e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—sarcoma	1.09e-06	9.36e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—sarcoma	1.03e-06	8.84e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—sarcoma	1.03e-06	8.81e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—sarcoma	9.85e-07	8.43e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—sarcoma	9.18e-07	7.86e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—sarcoma	8.78e-07	7.51e-06	CbGpPWpGaD
